Paper - WANFANG MED ONLINE

You Position: Home > Paper

Clinical selection of individualizd artificial liver support

( views:197, downloads:486 )

Author:: No author available

Journal Title:: Chinese Journal of Clinical Infectious Diseases

Issue:: 2

DOI:: 10.3760/cma.j.issn.1674-2397.2017.02.006

Key Word:: 肝功能衰竭;肝,人工;非生物型人工肝;杂合血液净化;个体化治疗;Liver failure;Liver,artificial;Non-biological artificial liver;Hybrid blood purification;Individual treatment

Abstract： Liver failure is characterized by hepatic encephalopathy, jaundice, hypo-coagulation and high mortality.Artificial liver support aims to temporarily replace hepatic function until liver function recover or bridge to liver transplantation.Individualized artificial liver support should be balanced and cover the following aspects: removing albumin bound toxins and/or water soluble toxins, eliminating inflammatory mediators and correcting blood coagulation disorders, in order to support metabolism and modulate immune function and to promote the regeneration of hepatocyte and reverse multiple organ failure that may lead to death of patients.Traditional non-biological artificial liver support can't meet individualized treatment.Recently developed hybrid blood purification model, such as albumin dialysis, fractionated plasma separation and adsorption (Prometheus system) and plasma diafiltration (PDF) have provided more and better choices for individualized artificial liver support.Based on the characteristics of pathophysiology and organ dysfunction of liver failure, the author has designed an alignment diagram of individualized artificial liver support for clinical selection.

Reference

[1]王宇,郭利民,熊号峰,等.不同成分血浆滤过透析治疗重型肝炎患者56例[J].2009,(23).
[2]郭利民.组合式人工肝治疗的原则与应用[J].2009,(5).
[3]中华医学会感染病学分会肝衰竭与人工肝学组.非生物型人工肝治疗肝衰竭指南（2016年版）[J].2016,(2).
[4]J, Kondrup,T, Almdal,H, Vilstrup,etc.High volume plasma exchange in fulminant hepatic failure.[J].1992,15(11).
[5]Karvellas,C.J.,Bagshaw,S.M..Advances in management and prognostication in critically ill cirrhotic patients[J].2014,20(2).
[6]Uwe, Heemann,Ulrich, Treichel,Jan, Loock,etc.Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study.[J].2002,36.
[7]Rela,M.,O'Grady,J.G.,Audimoolam,V.K.,etc.Lessons from look-back in acute liver failure? A single centre experience of 3300 patients[J].2013,59(1).
[8]Mitra K, Nadim,John A, Kellum,Andrew, Davenport,etc.Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.[J].2012,16(1).
[9]B.G Gazzard,M.J Weston,I.M Murray-Lyon,etc.Charcoal Hæmoperfusion in the Treatment of Fulminant Hepatic Failure[J].1974,303(7870).
[10]S S, Pedersen,S, Bro,P, Schlichting,etc.[Plasmapheresis as life-saving treatment in acute hepatic failure].[J].1993,155(10).
[11]J O, Clemmesen,F S, Larsen,E, Ejlersen,etc.Haemodynamic changes after high-volume plasmapheresis in patients with chronic and acute liver failure.[J].1997,9(1).
[12]Antoniades CG,Berry PA,Wendon JA,etc.The importance of immune dysfunction in determining outcome in acute liver failure.[J].2008,49(5).
[13]Juan Bisquert.Physical electrochemistry of nanostructured devices[J].2007,10(1).
[14]T, Sadahiro,H, Hirasawa,S, Oda,etc.Usefulness of plasma exchange plus continuous hemodiafiltration to reduce adverse effects associated with plasma exchange in patients with acute liver failure.[J].2001,29(7).
[15]Banares, Rafael,Catalina, Maria-Vega,Vaquero, Javier.Molecular Adsorbent Recirculating System and Bioartificial Devices for Liver Failure[J].2014,18(4).
[16]Koichiro, Shinozaki,Shigeto, Oda,Ryuzo, Abe,etc.Blood purification in fulminant hepatic failure.[J].2010,166.
[17]Nora Sipeki,Peter Antal-Szalmas,Peter L Lakatos,etc.Immune dysfunction in cirrhosis[J].2014,(10).
[18]F S, Larsen,B A, Hansen,L G, J?rgensen,etc.Cerebral blood flow velocity during high volume plasmapheresis in fulminant hepatic failure.[J].1994,17(6).
[19]Moreau, Richard,Arroyo, Vicente.Acute-on-Chronic Liver Failure: A New Clinical Entity[J].2015,13(5).
[20]S P, Wilkinson,M J, Weston,V, Parsons,etc.Dialysis in the treatment of renal failure in patients with liver disease.[J].1977,8(1).
[21]Wim Laleman,Alexander Wilmer,Pieter Evenepoel,etc.Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure[J].2006,10(4).
[22]William M. Lee,Julie Poison.AASLD Position Paper: The Management of Acute Liver Failure[J].2005,41(5).
[23]Andreas Bacher.Extracorporeal liver support with multipass albumin dialysis or plasmapheresis and filtering systems in acute liver failure[J].2011,31(s3).
[24]Ba?ares,R.,Nevens,F.,Larsen,F.S.,etc.Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial[J].2013,57(3).
[25]Hajime Nakae,Yutaka Eguchi,Takao Saotome,etc.Multicenter Study of Plasma Diafiltration in Patients With Acute Liver Failure[J].2010,14(5).
[26].High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial[J].2016,64(1).
[27]Larson,A.M.,Stravitz,R.T.,Lee,W.M..Introduction to the revised American Association for the Study of Liver Diseases position paper on acute liver failure 2011[J].2012,55(3).
[28]Mookerjee,R.P.,Olson,J.C.,Gines,P.,etc.Acute-on chronic liver failure[J].2012,57(6).
[29]Tsipotis, Evangelos,Shuja, Asim,Jaber, Bertrand L..Albumin Dialysis for Liver Failure: A Systematic Review[J].2015,22(5).
[30]Auzinger G,Wendon J,Dhawan A,etc.Acute liver failure.[J].2010,376(9736).
[31]Lee, Karla C. L.,Stadlbauer, Vanessa,Jalan, Rajiv.Extracorporeal liver support devices for listed patients[J].2016,22(6).
[32]V, Arroyo.New treatments for hepatorenal syndrome.[J].2000,6(3).
[33]O'Grady John G.,Gimson A.E.S.,O'Brien C.J.,etc.Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure[J].1988.
[34]H, Nakae,C, Yonekawa,H, Wada,etc.Effectiveness of combining plasma exchange and continuous hemodiafiltration (combined modality therapy in a parallel circuit) in the treatment of patients with acute hepatic failure.[J].2001,5(6).
[35]Stutchfield BM,Wigmore SJ,Simpson K.Systematic review and meta-analysis of survival following extracorporeal liver support.[J].2011,98(5).
[36]Achilles A, Demetriou,Robert S, Brown,Ronald W, Busuttil,etc.Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure.[J].2004,239(5).
[37]Andrés, Cárdenas,Pere, Ginès.Therapy insight: Management of hepatorenal syndrome.[J].2006,3.
[38]Thomas, Rimmelé,John A, Kellum.Clinical review: blood purification for sepsis.[J].2011,15(1).
[39]Kribben,A.,Gerken,G.,Haag,S.,etc.Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure[J].2012,142(4).
[40]D, Bihari,R D, Hughes,A E, Gimson,etc.Effects of serial resin hemoperfusion in fulminant hepatic failure.[J].1983,6(6).
[41]Jens Otto Clemmesen,Jens Kondrup,Lars Bo Nielsen,etc.Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure[J].2001,96(4).
[42]A, Davenport,E J, Will,A M, Davidson.Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure.[J].1993,21(3).
[43]Evenepoel P,Vanrenterghem Y,Claes K,etc.Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices.[J].2006,30(4).
[44]F S, Larsen,E, Ejlersen,B A, Hansen,etc.Systemic vascular resistance during high-volume plasmapheresis in patients with fulminant hepatic failure: relationship with oxygen consumption.[J].1995,7(9).
[45]A.E.S. Gimson,P.J. Mellon,S. Braude,etc.Earlier Charcoal Haemoperfusion in Fulminant Hepatic Failure[J].1982,320(8300).
[46]Nevens,F.,Laleman,W..Artificial liver support devices as treatment option for liver failure[J].2012,26(1).
[47]Jalan R,Kapoor D,Sen S,etc.Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis.[J].2003,38(1).
[48]Leckie,P.,Davenport,A.,Jalan,R..Extracorporeal liver support[J].2012,34(2).
[49]ustin.unimelb.edu.au,Bellomo R,Ronco C.Blood purification in the intensive care unit: evolving concepts.[J].2001,25(5).
[50]Wasmuth HE,Purucker EA,Matern S,etc.Patients with acute on chronic liver failure display "sepsis-like" immune paralysis.[J].2005,42(2).
[51]Krisper P,Stauber RE.Technology insight: artificial extracorporeal liver support--how does Prometheus compare with MARS?[J].2007,3(5).
[52]Saliba,F.,Camus,C.,Durand,F.,etc.Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: A randomized, controlled trial[J].2013,159(8).